Low dose naltrexone vs placebo
Induction of 5‐point endoscopic response CDEIS · Patients with active Crohn's disease
Low dose naltrexone may leads to higher induction of 5‐point endoscopic response CDEIS compared with placebo (low certainty).
1 finding from 1 review
- Low dose naltrexone for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes onlyRR 2.89 [1.18, 7.08]1 study · 34 participantsLow